



FINANCIAL TEAR SHEET

CORPORATE PROFILE


Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

STOCK INFORMATION

CHRS (Common Stock)

| | |
|--------------------|-----------------------|
| Exchange | NASDAQ (US Dollar) |
| Price | \$9.35 |
| Change (%) | ▲ 0.20 (2.19%) |
| Volume | 126,680 |
| 52 Week Low | \$8.05 |
| Market Cap | \$559,508,366 |
| Rolling EPS | -5.47 |
| PE Ratio | N/A |
| Shares Outstanding | 59,840,467 |

Data as of 02/22/18 12:42 p.m. ET



RECENT NEWS & UPCOMING EVENTS

01/02/18

[Coherus BioSciences Management to Present at The 36th Annual J.P. Morgan Healthcare Conference](#)

12/01/17

[Coherus BioSciences Management to Present at BMO's Prescriptions for Success Healthcare Conference](#)

11/06/17

[Coherus BioSciences Reports Third Quarter 2017 Operating and Financial Results](#)

There are currently no events scheduled.

SEC FILINGS

| Filing Date | Form |
|--------------------|-----------------|
| 02/14/18 | <u>SC 13G/A</u> |
| 02/14/18 | <u>SC 13G/A</u> |
| 02/14/18 | <u>SC 13D/A</u> |
| 02/13/18 | <u>SC 13G/A</u> |

CORPORATE GOVERNANCE

| | |
|-----------------------------------|-----------------------------|
| <u>Denny Lanfear</u> | President, CEO and Chairman |
| <u>Barbara Finck, M.D.</u> | Chief Medical Officer |
| <u>Alan Herman, Ph.D.</u> | Chief Scientific Officer |
| <u>Jean-Frederic Viret, Ph.D.</u> | Chief Financial Officer |
| <u>Peter Watler, Ph.D.</u> | Chief Technical Officer |
| <u>Vince Anicetti</u> | SVP, Global Quality |
| <u>Lisa M. Bell, Ph.D.</u> | SVP, Regulatory Affairs |
| <u>Michael Fleming</u> | SVP, Commercial Strategy |
| <u>Matthew R. Hooper</u> | SVP, General Counsel |

Data provided by Nasdaq. Minimum 15 minutes delayed.